Sign in
4

Changes in Ownership

Cardiff Oncology, Inc. Filed Acc 0001628280-23-008354

Options or other derivatives

  • Chief Executive Officer acquired 482,064 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Erlander Mark Chief Executive Officer 2023-03-15 Grant or award · Stock Options +482,064 1,664,477 D
Loading xslF345X03/wf-form4_167900288656705.xml…